Gunnar Kvalheim
Papers
1
Total Citations
30
H-Index
1
About
Gunnar Kvalheim is a pioneering oncologist whose research focuses on immunotherapy for high-risk prostate cancer, particularly through dendritic cell (DC) vaccines. His major contribution lies in demonstrating the feasibility and safety of personalized adjuvant DC vaccines after radical prostatectomy, aiming to prevent biochemical relapse in patients with aggressive disease. In a landmark Phase I/II study, Kvalheim showed that long-term administration of this vaccine could reduce recurrence risk, offering a new avenue for non-curative disease management. With over 30 citations, this work has influenced clinical trial design and sparked interest in combining DC vaccines with other immunotherapies. Kvalheim’s research bridges surgical oncology and cellular therapy, highlighting the potential of harnessing the immune system to target residual cancer cells. His achievements include advancing personalized medicine in urologic oncology and laying groundwork for larger efficacy trials. For students and researchers, Kvalheim’s work exemplifies translational research that moves from bench to bedside, addressing a critical unmet need in high-risk prostate cancer care.
Research Focus
Key Achievements
Top Papers
- 1